April 1, 2013 — Lantheus Medical Imaging Inc. announced a new supply contract with the Belgium-based Institute for Radioelements (IRE) to receive a supply of molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), for use in its TechneLite (Technetium Tc 99m Generator) generators.
Under the terms of the five-year agreement, IRE will provide an increasing supply of Mo-99 through Dec. 31, 2017. The new agreement also provides for the transition to Mo-99 sourced from Low-Enriched Uranium (LEU) upon IRE’s completion of its ongoing conversion program to modify its facilities and processes in accordance with Belgian nuclear security commitments.
“We are focused on enhancing our balanced and diverse supply chain for this important medical isotope to ensure that we consistently meet the needs of customers and their patients,” said Jeff Bailey, president and CEO of Lantheus Medical Imaging. “Over the course of this agreement, IRE will also help support our strategic initiatives related to supply chain stability and the conversion to 100 percent LEU-derived Mo-99.”
Lantheus has developed a globally diversified and balanced Mo-99 supply chain for the procurement of Mo-99. The company receives Mo-99 from four of the five major processors and seven of the eight associated reactors.
For more information: www.lantheus.com
July 30, 2024 
